Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqCM - Delayed Quote USD

Sunshine Biopharma, Inc. (SBFM)

Compare
2.0800
+0.1400
+(7.22%)
At close: April 1 at 4:00:00 PM EDT
3.1800
+1.10
+(52.88%)
After hours: April 1 at 7:59:59 PM EDT
Loading Chart for SBFM
  • Previous Close 1.9400
  • Open 1.9600
  • Bid 1.5000 x 200
  • Ask 2.5600 x 200
  • Day's Range 1.9600 - 2.0999
  • 52 Week Range 1.9000 - 248.0000
  • Volume 180,219
  • Avg. Volume 71,533
  • Market Cap (intraday) 5.633M
  • Beta (5Y Monthly) -1.48
  • PE Ratio (TTM) --
  • EPS (TTM) -127.9000
  • Earnings Date Apr 2, 2025 - Apr 3, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 300.00

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.

sunshinebiopharma.com

44

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SBFM

View More

Performance Overview: SBFM

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SBFM
30.67%
S&P 500 (^GSPC)
4.23%

1-Year Return

SBFM
99.03%
S&P 500 (^GSPC)
7.42%

3-Year Return

SBFM
99.95%
S&P 500 (^GSPC)
23.92%

5-Year Return

SBFM
99.96%
S&P 500 (^GSPC)
128.01%

Compare To: SBFM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SBFM

View More

Valuation Measures

Annual
As of 4/1/2025
  • Market Cap

    5.63M

  • Enterprise Value

    -6.00M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.01

  • Price/Book (mrq)

    0.23

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -12.82%

  • Return on Assets (ttm)

    -10.75%

  • Return on Equity (ttm)

    -17.98%

  • Revenue (ttm)

    32.96M

  • Net Income Avi to Common (ttm)

    -4.23M

  • Diluted EPS (ttm)

    -127.9000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.21M

  • Total Debt/Equity (mrq)

    2.22%

  • Levered Free Cash Flow (ttm)

    -12.84M

Research Analysis: SBFM

View More

Company Insights: SBFM

Research Reports: SBFM

View More

People Also Watch